North Atlantic Smaller
Companies Investment Trust PLC
("NASCIT", "the
Company")
GENERAL TEXT AMENDMENT
The following amendment has been
made to the Half-year Report announcement released on 25/09/2024 at
07:00 under RNS No. 5062F.
Detail Changed:
The date was wrongly stated as 31
January 2023 on the table under the 'Objective of the company and
financial highlights' section. The correct date should be 31
January 2024. In addition, certain non-material amendments were
made to the financial statements and notes.
Enquiries:
SGH Company Secretaries Limited,
Company Secretary
thomas.verlander@shma.co.uk
0207 264 4444
North Atlantic Smaller Companies Investment Trust
plc
Half-Yearly Report for the six months ended 31
July 2024
Registered in England and Wales number
1091347
objective of the company and financial
highlights
North Atlantic Smaller Companies Investment
Trust plc is a company incorporated and registered in England and
Wales.
The objective of the Company is to provide
capital appreciation through investment in a portfolio of smaller
companies principally based in countries bordering the North
Atlantic Ocean.
|
31 July
2024
(unaudited)
|
31 January
2024
(audited)
|
%
Change
|
Net asset value ("NAV") per 5p Ordinary
Share*:
|
|
|
|
Basic and diluted
|
5,551p
|
5,127p
|
8.3
|
Basic and diluted
adjusted#
|
5,766p
|
5,391p
|
7.0
|
Mid-market price of the 5p Ordinary
Shares
|
4,350p
|
3,690p
|
17.9
|
Discount to net asset value
|
21.6%
|
28.0%
|
|
Discount to adjusted net asset value
|
24.6%
|
31.6%
|
|
Standard & Poor's 500 Composite
Index†
|
4,301.9
|
3,810.1
|
12.9
|
Russell 2000 Index†
|
1,756.2
|
1,531.2
|
14.7
|
Ongoing charges (annualised)
|
1.2%
|
1.2%
|
|
* Includes current period revenue.
# Adjusted to reflect
Oryx International Growth Fund plc ("Oryx") under the equity method
of accounting, which is how the Company previously accounted for
its share of Oryx, prior to the adoption of IFRS 10. This is useful
to the shareholder as it shows the NAV based on valuing Oryx at
NAV. See note 6.
† Sterling adjusted.
chief executive's review
During the six months under review the net
asset value adjusted for the dividend payment rose by 8.3% compared
to a rise in the sterling adjusted Standard and Poor's index of
12.9%. Performance was adversely impacted by the Trust's large cash
holdings and the underperformance of the Private Equity Portfolio
although I expect that as a number of sales come through over the
next few months this will be reversed.
The Trust reported net income for the period of
£8,076,000 (2023: £4,615,000). Consistent with prior years no
divided is being declared until the outcome for the current year
becomes clearer. However based on my current expectations, it is
anticipated that dividends in respect of the financial year ending
January 2025 will comfortably exceed that paid in respect of fiscal
2024.
During the six month period the Trust purchased
approximately 178,237 shares for cancellation at a discount to NAV
of approximately 30%. This policy which is ongoing increased the
NAV for all long term shareholders and helped to modestly reduce
the discount compared to the end of January 2024, net asset value,
at a time when many other trusts, particularly those with unquoted
holdings, have seen a significant widening.
quoted portfolio
Quoted markets performed well over the period,
helped by a number of takeovers which sadly did not benefit the
Trust. Nevertheless, the performance of the quoted portfolio as a
whole was a rise broadly in line with the comparable UK
indices.
Stocks that performed notably well included
Pinewood Technology at 50%, Gleeson at +22%, Hargreaves Services at
+21.5%, Paypoint +26%, Polar Capital +33%, TP ICAP +17.5% and
Restore +15.5% since purchase. On the other hand EKF fell by 8%
despite very encouraging results and Niox only rose 2% despite
excellent early growth. Frenkel Topping was also flat following
concerns as to how the FCA application of the Consumer Duty issues
might adversely impact the business.
unquoted portfolio
The UK Portfolio rose 2% during the period as
there were no major realisations. However, this is expected to
change over the next few months following a recent bid for Journey
Group and the likely sale of another substantial holding at good
premium to the end of July valuation.
The United States portfolio which was
relatively small at £28 million was flat during the period. In
reality there are only two investments, Crest Foods which was
acquired in February and is performing in line with expectations
and Performance Chemicals which is under offer at a modest premium
to the July valuation.
outlook
August saw very considerable turbulence in the
financial markets, although other than the fall in Polar Capital
which reduced the NAV by 0.6%, the impact on the balance of the
portfolio was negligible. It is therefore frustrating to see the
share price fall by 7%.
I have had a chance to meet with all our major
quoted holdings over the past three weeks and in not a single case
do I see cause for alarm and in some cases such as Spire Health we
will be adding to the holdings if we can find attractive entry
points. I am also hopeful that some of our indirect holdings
through Oryx and Odyssean will be subject to corporate activity in
the coming months.
Our unquoted portfolio is, I believe, well
positioned to build value for shareholders both in the short and
long term and it would be disappointing if it failed to deliver
over £40 million of capital over the next eighteen months at a good
uplift from the current valuations.
In short I remain optimistic for the portfolio
as a whole and shareholder returns will hopefully be enhanced by a
higher dividend and further share buybacks over the course of the
next twelve months.
Finally is it my intention that in addition to
the shareholder annual general meeting, there will be a meeting of
shareholders towards the end of each calendar year which will be
announced through an RNS. I very much hope you will be able to join
us.
C H B Mills
Chief Executive
24 September 2024
top ten investments as at 31 July 2024
|
|
Fair
value
£'000
|
% of
net assets
|
Oryx International Growth Fund
Limited*
|
UK Quoted
|
106,249
|
14.4
|
US Treasury Bills
|
US Treasury Stock
|
64,095
|
8.7
|
Polar Capital Holdings Plc
|
UK Quoted on AIM
|
42,000
|
5.7
|
Hargreaves Services Plc
|
UK Quoted on AIM
|
38,304
|
5.2
|
Harwood Private Equity Fund V LP
|
UK Unquoted
|
34,388
|
4.7
|
MJ Gleeson Group Plc
|
UK Quoted
|
30,952
|
4.2
|
Odyssean Investment Trust Plc
|
UK Quoted
|
27,520
|
3.7
|
Conduit Holdings Limited
|
UK Quoted
|
26,150
|
3.5
|
EKF Diagnostics Holdings Plc
|
UK Quoted on AIM
|
26,112
|
3.5
|
Niox Group Plc
|
UK Quoted on AIM
|
23,250
|
3.2
|
|
|
|
|
|
|
419,020
|
56.8
|
* Traded Price under IFRS10, incorporated in
Guernsey.
All investments are valued at fair
value.
interim management report
investment objective
The objective of North Atlantic Smaller
Companies Investment Trust PLC is to provide capital appreciation
to its shareholders through investing in a portfolio of smaller
companies which are principally based in countries bordering the
North Atlantic Ocean.
material events
There were no material events during the
period.
material transactions
There were no material transactions during the
period.
risk profile
The principal risks and uncertainties for the
remaining six months of the year continue to be as described in the
Annual Report for the year ended 31 January 2024. The principal
risks arising from the Company's financial instruments are market
price risk, including currency risk, interest rate risk and other
price risk, liquidity risk and credit risk. The Directors review
and agree policies with the Manager, Harwood Capital LLP, for
managing these risks. The policies have remained substantially
unchanged in the six months since the year end.
The Company does not have any significant
exposure to credit risk arising from any one individual party.
Credit risk is spread across a number of counterparties, each
having an immaterial effect on the Company's cash flows, should a
default happen. The Company assesses the credit worthiness of its
debtors from time to time to ensure that they are neither past due
or impaired.
To support its investment in unquoted companies,
the Company may periodically agree to guarantee all or part of the
borrowings of investee companies. Provision is made for any costs
that may be incurred when the Directors consider it likely that the
guarantee will crystallise.
The Company's exposure to market price risk
comprises mainly movements in the value of the Company's
investments. It should be noted that the prices of options tend to
be more volatile than the prices of the underlying securities. The
Manager assesses the exposure to market risk when making each
investment decision and monitors the overall level of market risk
on the whole of the investment portfolio on an ongoing
basis.
The functional and presentational currency of
the Company is Sterling, and therefore, the Company's principal
exposure to foreign currency risk comprises investments priced in
other currencies, principally US Dollars.
The Company invests in equities and other
investments that are realisable.
related party transactions
These are listed in note 9 to the half yearly
condensed financial statements.
By Order of the Board
Sir Charles
Wake
Chairman
24 September 2024
responsibility statement
The Directors confirm to the best of their
knowledge that:
·
The condensed set of financial statements contained within
this half yearly financial report have been prepared in accordance
with International Accounting Standard ("IAS") 34 'Interim
Financial Reporting' in conformity with the requirement of the
Companies Act 2006 and gives a true and fair view of the assets,
liabilities, financial position and profit of the Company;
and
·
The half yearly financial report includes a fair review of
the information required by the FCA's Disclosure and Transparency
Rule 4.2.7R being disclosure of important events that have occurred
during the first six months of the financial year, their impact on
the condensed set of financial statements and a description of the
principal risks and uncertainties for the remaining six months of
the year; and
·
The half yearly financial report includes a fair review of
the information required by the Disclosure and Transparency Rule
4.2.8R being disclosure of related party transactions during the
first six months of the financial year, how they have materially
affected the financial position of the Company during the period
and any changes therein.
The half yearly financial report was approved by
the Board on 24 September 2024 and the above responsibility
statement was signed on its behalf by:
Sir Charles Wake
Chairman
24 September 2024
condensed statement of comprehensive income
(unaudited)
|
Six months ended
31 July
2024
|
Six
months ended
31 July
2023
|
Year
ended
31 January
2024
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
12,416
|
-
|
12,416
|
8,922
|
-
|
8,922
|
20,817
|
-
|
20,817
|
Net gains/ (losses) on investments at
fair value
|
-
|
55,123
|
55,123
|
-
|
(27,643)
|
(27,643)
|
-
|
(9,539)
|
(9,539)
|
Currency exchange
gains/(losses)
|
-
|
81
|
81
|
-
|
(669)
|
(669)
|
-
|
(523)
|
(523)
|
|
|
|
|
|
|
|
|
|
|
total income
|
12,416
|
55,204
|
67,620
|
8,922
|
(28,312)
|
(19,390)
|
20,817
|
(10,062)
|
10,755
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
Investment management fee (note
9)
|
(3,629)
|
-
|
(3,629)
|
(3,561)
|
-
|
(3,561)
|
(7,122)
|
-
|
(7,122)
|
Other expenses
|
(699)
|
-
|
(699)
|
(731)
|
-
|
(731)
|
(1,449)
|
-
|
(1,449)
|
|
|
|
|
|
|
|
|
|
|
return before finance costs and taxation
|
8,088
|
55,204
|
63,292
|
4,630
|
(28,312)
|
(23,682)
|
12,246
|
(10,062)
|
2,184
|
|
|
|
|
|
|
|
|
|
|
Finance costs
|
-
|
-
|
-
|
-
|
-
|
-
|
(6)
|
-
|
(6)
|
|
|
|
|
|
|
|
|
|
|
return before taxation
|
8,088
|
55,204
|
63,292
|
4,630
|
(28,312)
|
(23,682)
|
12,240
|
(10,062)
|
2,178
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(12)
|
-
|
(12)
|
(15)
|
-
|
(15)
|
(30)
|
-
|
(30)
|
|
|
|
|
|
|
|
|
|
|
return for the period
|
8,076
|
55,204
|
63,280
|
4,615
|
(28,312)
|
(23,697)
|
12,210
|
(10,062)
|
2,148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
earnings per ordinary share (note 5)
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
472.5p
|
|
|
(174.9p)
|
|
|
15.9p
|
The total column of the statement is the
Statement of Comprehensive Income of the Company prepared in
accordance with International Financial Reporting Standards
("IFRS") in conformity with the requirement of the Companies Act
2006.
The supplementary revenue and capital columns
are presented for information purposes as recommended by the
Statement of Recommended Practice ("SORP") issued by the
Association of Investment Companies ("AIC").
All items in the above Statement derive from
continuing operations. No operations were acquired or discontinued
in the period.
The accompanying notes are an integral part of
these financial statements.
condensed statement of changes in equity
(unaudited)
|
Share
capital
£'000
|
Capital
redemption
reserve
£'000
|
Share
premium
£'000
|
Capital
reserve
£'000
|
Revenue
reserve
£'000
|
Total
£'000
|
six
months ended 31 July 2024
|
|
|
|
|
|
|
31 January 2024
|
673
|
197
|
1,301
|
670,168
|
17,891
|
690,230
|
Total comprehensive income for the
period
|
-
|
-
|
-
|
55,204
|
8,076
|
63,280
|
Shares purchased for
cancellation
|
(9)
|
9
|
-
|
(6,986)
|
-
|
(6,986)
|
Dividend
|
-
|
-
|
-
|
-
|
(9,195)
|
(9,195)
|
|
|
|
|
|
|
|
31 July 2024
|
664
|
206
|
1,301
|
718,386
|
16,772
|
737,329
|
|
|
|
|
|
|
|
six
months ended 31 July 2023
|
|
|
|
|
|
|
31 January 2023
|
680
|
190
|
1,301
|
685,504
|
5,681
|
693,356
|
Total comprehensive (loss)/income
for the period
|
-
|
-
|
-
|
(28,312)
|
4,615
|
(23,697)
|
Shares purchased for
cancellation
|
(4)
|
4
|
-
|
(2,828)
|
-
|
(2,828)
|
|
|
|
|
|
|
|
31 July 2023
|
676
|
194
|
1,301
|
654,364
|
10,296
|
666,831
|
|
|
|
|
|
|
|
year ended 31 January 2024
|
|
|
|
|
|
|
31 January 2023
|
680
|
190
|
1,301
|
685,504
|
5,681
|
693,356
|
Total comprehensive income for the
year
|
-
|
-
|
-
|
(10,062)
|
12,210
|
2,148
|
Shares purchased for
cancellation
|
(7)
|
7
|
-
|
(5,274)
|
-
|
(5,274)
|
|
|
|
|
|
|
|
31 January 2024
|
673
|
197
|
1,301
|
670,168
|
17,891
|
690,230
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of
these financial statements.
condensed balance sheet (unaudited)
|
As at
31 July
2024
£'000
|
As at
31 July
2023
£'000
|
As at
31 January
2024
£'000
|
non
current assets
|
|
|
|
Investments at fair value through
profit or loss
|
700,544
|
635,150
|
612,425
|
|
|
|
|
|
700,544
|
635,150
|
612,425
|
current assets
|
|
|
|
Trade and other
receivables
|
9,231
|
6,329
|
69,272
|
Cash and cash equivalents
|
28,149
|
27,699
|
9,203
|
|
|
|
|
|
37,380
|
34,028
|
78,475
|
|
|
|
|
total assets
|
737,924
|
669,178
|
690,900
|
|
|
|
|
current liabilities
|
|
|
|
Trade and other payables
|
(595)
|
(2,347)
|
(670)
|
|
|
|
|
total liabilities
|
(595)
|
(2,347)
|
(670)
|
|
|
|
|
total assets less current liabilities
|
737,329
|
666,831
|
690,230
|
|
|
|
|
net
assets
|
737,329
|
666,831
|
690,230
|
|
|
|
|
represented by:
|
|
|
|
Share capital
|
664
|
676
|
673
|
Capital redemption reserve
|
206
|
194
|
197
|
Share premium account
|
1,301
|
1,301
|
1,301
|
Capital reserve
|
718,386
|
654,364
|
670,168
|
Revenue reserve
|
16,772
|
10,296
|
17,891
|
|
|
|
|
total equity attributable to equity holders of the
company
|
737,329
|
666,831
|
690,230
|
|
|
|
|
net
asset value per ordinary share (note 6):
|
|
|
|
Basic and diluted
|
5,551p
|
4,929p
|
5,127p
|
The accompanying notes are an integral part of
these financial statements.
condensed cash flow statement (unaudited)
|
Six months ended
31 July
2024
£'000
|
Six months
ended
31 July
2023
£'000
|
Year
ended
31 January
2024
£'000
|
cash flows from operating activities
|
|
|
|
Investment income
received
|
7,173
|
6,752
|
17,362
|
Deposit interest received
|
719
|
96
|
765
|
Investment Manager's fees and
performance fees paid
|
(3,636)
|
(3,517)
|
(7,078)
|
Other cash payments
|
(870)
|
(876)
|
(1,581)
|
|
|
|
|
cash received from operations (note 7)
|
3,386
|
2,455
|
9,468
|
Taxation paid
|
(12)
|
(15)
|
(30)
|
|
|
|
|
net
cash inflow from operating activities
|
3,374
|
2,440
|
9,438
|
|
|
|
|
cash flows from investing activities
|
|
|
|
Purchases of investments
|
(158,833)
|
(204,318)
|
(424,801)
|
Sales of investments
|
190,162
|
227,331
|
424,503
|
|
|
|
|
net
cash inflow/(outflow) from
investing activities
|
31,329
|
23,013
|
(298)
|
|
|
|
|
cash flows from financing activities
|
|
|
|
Dividend paid
|
(9,195)
|
(2,992)
|
(2,992)
|
Repurchase of Ordinary Shares for
cancellation
|
(6,985)
|
(2,828)
|
(5,274)
|
|
|
|
|
net
cash outflow from financing activities
|
(16,180)
|
(5,820)
|
(8,266)
|
|
|
|
|
increase in
cash and cash equivalents for the period
|
18,523
|
19,633
|
874
|
cash and cash
equivalents at the start of the period
|
9,203
|
9,010
|
9,010
|
Revaluation of foreign currency
balances
|
423
|
(944)
|
(681)
|
|
|
|
|
cash and cash equivalents at the end of the
period
|
28,149
|
27,699
|
9,203
|
|
|
|
|
The accompanying notes are an integral part of
these financial statements.
notes to the financial statements (unaudited)
1. a) basis of accounting
North Atlantic Smaller Companies Investment
Trust plc is a company incorporated and registered in England and
Wales. The principal activity of the Company is that of an
investment trust company within the meaning of Sections 1158/1159
of the Corporation Tax Act 2010.
The condensed financial statements of the
Company have been prepared in accordance with International
Accounting Standard ("IAS") 34 - "Interim Financial Reporting" in
conformity with the requirement of the Companies Act 2006. The
accounting policies and methods of computation followed in these
half-yearly condensed financial statements are consistent with the
most recent annual financial statements for the year ended 31
January 2024 included in the Annual Report.
The financial statements have also been prepared
in accordance with the AIC SORP for the financial statements of
investment trust companies and venture capital trusts, except to
any extent where it is not consistent with the requirements of
IFRS.
The financial information contained in this
Half-Yearly Report does not constitute statutory accounts as
defined in the Companies Act 2006. The financial information for
the periods ended 31 July 2024 and 31 July 2023 have not been
audited or reviewed by the Company's Auditor. The figure and
financial information for the year ended 31 January 2024 are an
extract from the latest published audited financial statements,
which have been filed with the Registrar of Companies. The report
of the Auditor on those financial statements was unqualified and
did not contain a statement under either Section 498(2) or 498(3)
of the Companies Act 2006.
b) functional currency
The functional currency of the Company is Pounds
Sterling because this is the primary economic currency in which the
Company operates. The financial statements are presented in Pounds
Sterling rounded to the nearest thousand, except where otherwise
indicated.
c) significant accounting policies
The accounting policies applied are consistent
with those of the Annual Financial Report for the year ended 31
January 2024. Since the year end no new standards have been
adopted.
d) accounting developments
In the current period, the Company has applied a
number of amendments to IFRS, issued by the IASB mandatorily
effective for an accounting period that begins on or after 1
January 2024. These include annual improvements to IFRS, changes in
standards, legislative and regulatory amendments, changes in
disclosure and presentation requirements. The adoption of these has
not had any material impact on these condensed financial
statements.
e) segmental reporting
The Directors are of the opinion that the
Company is engaged in a single segment of business, being
investment business. The Company invests in smaller companies
principally based in countries bordering the North Atlantic
Ocean.
f) going concern
The financial statements have been prepared on a
going concern basis and on the basis that approval as an investment
trust company will continue to be met. The Directors have made an
assessment of the Company's ability to continue as a going concern
and are satisfied that the Company has the resources to continue in
business for the foreseeable future, being a period of 12 months
from the date when these financial statements were approved. The
Directors are of the view that the Company can meet its obligations
as and when they fall due. The cash and US treasury bills available
enables the Company to meet any funding requirements and finance
future additional investments. The Company is a closed-end fund,
where assets are not required to be liquidated to meet day-to-day
redemptions.
2. investment management and performance fees
A Performance Fee is only payable if the
investment portfolio, including Oryx at the adjusted price,
outperforms the Sterling adjusted Standard & Poor's 500
Composite Index at the end of each financial year and is limited to
a maximum payment of 0.5% of Shareholders' Funds, and is allocated
100% to capital.
An amount would be included in these financial
statements for the Performance Fee that could be payable based on
investment performance to 31 July 2024. At that date, no
Performance Fee, inclusive of VAT, has been accrued for in the
accounts (31 July 2023: £nil; 31 January 2024: £nil).
Further details of fees paid to the investment
manager can be found in Note 9, Related Party
transactions.
3. taxation
The Company has an effective tax rate of 0%. The
estimated effective tax rate is 0% as investment gains are exempt
from tax owing to the Company's status as an Investment Trust and
there is expected to be an excess of management expenses over
taxable income and thus there is no charge for corporation
tax.
During the half year to 31 July 2024, the
Company recognised a total charge of £12,000 (half year to 31 July
2023: £15,000, year ended 31 January 2024: £30,000), representing
irrecoverable withholding tax paid on overseas investment
income.
4. dividends
For the year ended 31 January 2024, the Board
declared an interim dividend of 68.5p per Ordinary share (31
January 2023: 22p) which was paid on 28 March 2024. For the year
end 31 January 2024, no final dividend was proposed (31 January
2023; nil).
5. earnings per ordinary share
|
|
Revenue
|
|
|
Capital
|
|
|
Total
|
|
|
Net
return
£'000
|
Ordinary
Shares
|
Per
Share
pence
|
Net
return
£'000
|
Ordinary
Shares
|
Per
Share
pence
|
Net
return
£'000
|
Ordinary
Shares
|
Per
Share
pence
|
six
months ended 31 July 2024
|
|
|
|
|
|
|
|
Basic and diluted return per
Share
|
8,076
|
13,392,121
|
60.3
|
55,204
|
13,392,121
|
412.2
|
63,280
|
13,392,121
|
472.5
|
|
|
|
|
|
|
|
|
|
|
six
months ended 31 July 2023
|
|
|
|
|
|
|
|
Basic and diluted return per
Share
|
4,615
|
13,546,346
|
34.1
|
(28,312)
|
13,546,346
|
(209.6)
|
(23,697)
|
13,546,346
|
(174.9)
|
|
|
|
|
|
|
|
|
|
|
year ended 31 January 2024
|
|
|
|
|
|
|
|
Basic and diluted return per
Share
|
12,210
|
13,508,610
|
90.4
|
(10,062)
|
13,508,610
|
(74.5)
|
2,148
|
13,508,610
|
15.9
|
Basic return per Ordinary Share has been
calculated using the weighted average number of Ordinary Shares in
issue during the period.
6. net asset value per ordinary
share
The basic net asset value per Ordinary Share is
based on net assets of £737,329,000 (31 July 2023: £666,831,000; 31
January 2024: £690,230,000) and on 13,283,338 Ordinary Shares (31
July 2023: 13,527,634; 31 January 2024: 13,461,575) being the
number of Ordinary Shares in issue at the period end.
During the period to 31 July 2024, there were
178,237 shares bought back for cancellation at a cost, including
stamp duty of £6,986,000 (31 July 2023: 74,434 shares bought back
for cancellation at a cost, including stamp duty of £2,828,000; 31
January 2024: 140,493 shares at a cost, including stamp duty of
£5,274,000).
adjustment for Oryx
The Company has also reported an adjusted net
asset value per share using equity accounting, in accordance with
its previous method of valuing its investment in Oryx. The Company
has chosen to report this net asset value per share to show the
difference derived if equity accounting were to be used. Equity
accounting permits the use of net asset value pricing for listed
assets which in the case of Oryx is higher than its fair
value.
The values of Oryx, as at each period end, are
as follows:
|
31 July 2024 £'000
|
31 July 2023
£'000
|
31 January 2024
£'000
|
Oryx at Fair value (traded price)
|
106,249
|
81,494
|
83,706
|
Oryx value using Equity Accounting
|
134,831
|
114,534
|
119,254
|
Increase in net assets using Equity
Accounting
|
28,582
|
33,040
|
35,548
|
|
31 July 2024
|
31 July
2023
|
31 January
2024
|
Net asset value per Share
|
|
|
|
- Basic and diluted
|
5,551p
|
4,929p
|
5,127p
|
|
|
|
|
Net asset value per Share adjusted
|
|
|
|
- Basic and diluted
|
5,766p
|
5,174p
|
5,391p
|
7. reconciliation of total return before taxation to cash
received from operations
|
Six months
ended
31 July 2024
£'000
|
Six months
ended
31 July
2023
£'000
|
Year ended
31 January
2024
£'000
|
Total return before taxation
|
63,292
|
(23,682)
|
2,178
|
(Gains)/losses on investments and
currency
|
(55,204)
|
28,312
|
10,062
|
Income reinvested
|
(133)
|
-
|
(549)
|
Increase in trade and other
receivables
|
(4,493)
|
(2,074)
|
(2,186)
|
Decrease in trade and other payables
|
(76)
|
(101)
|
(37)
|
|
|
|
|
Cash received from operations
|
3,386
|
2,455
|
9,468
|
|
|
|
|
8. investments
financial assets at fair value through profit or
loss
This requires the Company to classify fair value
measurements using a fair value hierarchy that reflects the
significance of the inputs used in making the measurements. The
fair value hierarchy consists of the following three
levels:
·
Level 1 - Quoted prices (unadjusted) in active markets for
identical assets or liabilities.
·
Level 2 - Inputs other than quoted prices included within
Level 1 that are observable for the asset or liability, either
directly (that is, as prices) or indirectly (that is, derived from
prices).
·
Level 3 - Inputs for the asset or liability that are not
based on observable market data (unobservable inputs).
The level in the fair value hierarchy within
which the fair value measurement is categorised in its entirety is
determined on the basis of the lowest level input that is
significant to the fair value measurement in its
entirety.
For this purpose, the significance of an input
is assessed against the fair value measurement in its entirety. If
a fair value measurement uses observable inputs that require
significant adjustment based on unobservable inputs, that
measurement is a Level 3 measurement. Assessing the significance of
a particular input to the fair value measurement in its entirety
requires judgement, considering factors specific to the asset or
liability.
The determination of what constitutes
'observable' requires significant judgement by the Company. The
Company considers observable data from investments actively traded
in organised financial markets; fair value is generally determined
by reference to Stock Exchange quoted market bid prices at the
close of business on the Balance Sheet date, without adjustment for
transaction costs necessary to realise the asset.
The table below sets out fair value measurements
as at the period end, by the level in the fair value hierarchy into
which the fair value measurement is categorised.
six months ended 31 July 2024
|
Total
£'000
|
Level 1
£'000
|
Level 2
£'000
|
Level 3
£'000
|
Equity investments
|
596,202
|
478,796
|
-
|
117,406
|
Fixed interest investments
|
104,342
|
64,095
|
-
|
40,247
|
Total
|
700,544
|
542,891
|
-
|
157,653
|
|
|
|
|
|
six months ended 31 July 2023
|
Total
£'000
|
Level 1
£'000
|
Level 2
£'000
|
Level 3
£'000
|
Equity investments
|
524,318
|
412,203
|
-
|
112,115
|
Fixed interest investments
|
110,832
|
80,612
|
-
|
30,220
|
Total
|
635,150
|
492,815
|
-
|
142,335
|
|
|
|
|
|
year ended 31 January 2024
|
Total
£'000
|
Level 1
£'000
|
Level 2
£'000
|
Level 3
£'000
|
Equity investments
|
519,988
|
414,074
|
-
|
105,914
|
Fixed interest investments
|
92,437
|
60,757
|
-
|
31,680
|
Total
|
612,425
|
474,831
|
-
|
137,594
|
reconciliation of level 3 movement - financial assets at
31 July 2024
|
Total
£'000
|
Equity
investments
£'000
|
Fixed interest
investments
£'000
|
Opening fair value at 31 January 2024
|
137,594
|
105,914
|
31,680
|
Purchases
|
27,923
|
18,191
|
9,732
|
Sales
|
(5,890)
|
(5,145)
|
(745)
|
Total losses included in losses on investments
in the statement of comprehensive income:
|
|
|
|
- on assets sold
|
(71)
|
(20)
|
(51)
|
- on assets held at the end of the
period
|
(1,903)
|
(1,534)
|
(369)
|
Closing fair value
|
157,653
|
117,406
|
40,247
|
unquoted at directors' estimate of fair value
Unquoted investments are valued in accordance
with the International Private Equity and Venture Capital Valuation
("IPEV") Guidelines. Their valuation incorporates all factors that
market participants would consider in setting a price. The primary
valuation techniques employed to value the unquoted investments are
earnings multiples, recent transactions and the net asset basis.
Valuations in local currency are translated into Sterling at the
exchange rate ruling on the Balance Sheet date.
Included within the Statement of Comprehensive
Income as at 31 July 2024, is a loss of £1,903,000 relative to the
movement in the fair value of the unquoted investments valued using
IPEV valuation techniques.
the valuation techniques applied are based on the
following assumptions:
Unquoted investments are usually valued by
reference to the valuation multiples of similar listed companies or
from transactions of similar businesses. Where appropriate
discounts are then applied to those comparable multiples to reflect
differences in size and liquidity. These enterprise values are then
adjusted for net debt to arrive at an equity valuation. Where
companies are in compliance with the loan note terms these loans
are generally held at par plus accrued interest (where applicable)
unless the enterprise value suggests that the debt cannot be
recovered.
9. related party transactions
There have been no changes to the related party
arrangements or transactions as reported in the Statutory Annual
Financial Report for the year ended 31 January 2024.
The Administrator, Harwood Capital LLP, is
regarded as a related party of the Company. The amounts incurred by
Harwood Capital LLP and Growth Financial Services Limited in
respect of investment management for the period are as
follows:
|
Six months ended
31 July 2024
£'000
|
Six months
ended
31 July
2023
£'000
|
Year ended
31 January
2024
£'000
|
Fees due to Harwood Capital LLP
|
2,177
|
2,137
|
4,273
|
Fees due to GFS
|
1,452
|
1,424
|
2,849
|
Performance fee
|
-
|
-
|
-
|
|
3,629
|
3,561
|
7,122
|
At 31 July 2024, £363,000 was payable to Harwood
Capital in respect of outstanding management fees (31 July 2023:
£356,000, 31 January 2024: £356,000). At 31 July 2024, there was no
fee payable to GFS in respect of outstanding performance fees (31
July 2023: £nil, 31 January 2024: £nil) net of VAT.
Fees paid to Directors, for the six months ended
31 July 2024 amounted to £109,000 (six months ended 31 July 2023:
£97,000; year ended 31 January 2024: £206,000).
At 31 July 2024, £18,000 was payable to
Directors in respect of outstanding fees (31 July 2023: £18,000, 31
January 2024 £18,000).
During the half year to 31 July 2024, £85,000
was transferred to the Company's 100% owned subsidiary Consolidated
Venture Finance Limited ("CVF"). During the same period CVF bought
two investments from the Company at a cost of £84,000.
shareholder information
financial calendar
Announcement of results and annual
report
|
May
|
Annual General Meeting
|
June
|
Half Yearly figures announced
|
September
|
Half Yearly Report posted
|
September
|
share price
The Company's mid-market share price is quoted
daily in the Financial Times appearing under "Investment
Companies".
It also appears on:
SEAQ Ordinary Shares: NAS
Trustnet:
www.trustnet.com
net asset value
The latest net asset value of the Company can be
found on the Company's website: www.nascit.co.uk
share dealing
Investors wishing to purchase more Ordinary
Shares or dispose of all or part of their holding may do so through
a stockbroker. Many banks also offer this service.
The Company's registrars are Link Group. In the
event of any queries regarding your holding of shares, please
contact the registrars on: 0871 664 0300, or by email on
enquiries@linkgroup.co.uk
Changes of name or address must be notified to
the registrars in writing at:
Link Group
Central Square
29 Wellington Street
Leeds LS1 4DL
Directors
Sir Charles Wake (Chairman)
Christopher Mills (Chief Executive)
Professor Fiona Gilbert
Lord Howard of Rising
G Walter Loewenbaum
Peregrine Moncreiffe
Julian Fagge
Administrator
Harwood Capital LLP
(Authorised
and regulated by the Financial Conduct Authority)
6 Stratton Street
Mayfair
London W1J 8LD
Telephone: 020 7640 3200
Financial Adviser and Stockbroker
Winterflood Investment Trusts
Riverbank House
2 Swan Lane
London EC4R 3GA
Registered Office
6 Stratton Street
Mayfair
London W1J 8LD
Telephone: 020 7640 3200
Registrars
Link Group
Central Square
29 Wellington Street
Leeds LS1 4DL
Auditors
RSM UK Audit LLP
25 Farringdon Street
London EC4A 4AB
Company Secretary
SGH Company Secretaries Limited
60 Gracechurch Street
London EC3V 0HR